CREATES Act and 180-day exclusivity reforms also in legislation headed to US House floor, even as generic industry remains opposed to two of the three main provisions. The Rx pricing language is bundled with Obamacare language designed to force a tough vote by Republicans.
You might think that legislation which is projected to increase use of an industry's product and save the government money at the same time would be popular with the firms slated to see a sales increase. Well, when you are the star-crossed generics industry, you'd be wrong.
Legislation in the US House aimed at lowering drug cost by bolstering generic and biosimilar competition would save the federal government nearly $5bn in spending over 10 years, according to the Congressional Budget Office
European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.
Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.
